Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 2von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Hamartoma Syndrome, Multiple 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Autistic Disorder 1Astrocytoma 1

Interventions

Temozolomide 6Radiosurgery 6pembrolizumab 4Magnetic Resonance Spectroscopy 4Bevacizumab 4Specimen Handling 3Nivolumab 3abemaciclib 2Watchful Waiting 2Surveys and Questionnaires 2Receptors, Interleukin-8B 2Radiation 2Mental Status and Dementia Tests 2Memantine 2Ipilimumab 2Biopsy 2vorasidenib 1sotorasib 1sapanisertib 1ribociclib 1pertuzumab 1osimertinib 1lenvatinib 1fluciclovine F-18 1entrectinib 1encorafenib 1elacestrant 1brivaracetam 1binimetinib 1Valacyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Everolimus × 30 days × Clear all
NCT05843253 2026-05-29

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡